FT Global Pharmaceutical and Biotechnology Conference 2014 - Highlights

| December 9, 2014

article image
The future is arriving fast for the life science industry. Convergence is happening along the entirety of the industry value chain, blurring the boundaries between pharma, biotech, generics, devices and broader healthcare companies. Advanced technologies and materials, once the realm of science fiction, are now starting to emerge and can be expected to play a much greater role in the research efforts of life science companies in the future. Emerging market companies are expanding and edging their way to the top table as innovator drug companies.

Spotlight

Nanomi

Over Nanomi: Nanomi ontwikkelt Nano en Microdeeltjes voor de farmaceutische industrie door middel van onze microfluidic Monosphere Technology. Wij zijn het “center of excellence for complex injectables” van Lupin ltd, een internationaal Indiaas farmaceutisch concern. Nanomi is een internationale, hightech omgeving met een leuke, informele werksfeer. Company Profile: Nanomi, based in Oldenzaal, is a drug delivery company developing pharmaceutical products based on nano- and microparticles. These particles are developed by using Nanomi’s microfluidic Monosphere Technology, enabling the manufacturing of very unique and uniform custom-made particles for a broad range of pharmaceutical products. In 2014 Nanomi was acquired by Lupin and became its center of excellence for complex injectables. Nanomi offers a highly innovative as well as dynamic environment and benefits from its parent company that was founded in 1968. Lupin is an innovation led transnational pharmaceutical company developing

OTHER ARTICLES

How AI and Big Data Will Disrupt Pharma’s Regulatory Compliance Standards

Article | March 4, 2020

The industry as we know it is changing. Pharmaceutical and life sciences companies across the globe are experiencing more pressure than ever to keep up with increased regulatory standards while moving at a pace that requires them to innovate in order to remain competitive. With more real-time automation and the steady increase in AI and Big Data sweeping the landscape, what used to be a slow-to-change and risk-averse industry is now expected to see a significant shift towards newer technology that focus on heightened regulatory standards. Here’s how your company can get ahead of what industry experts are calling, Pharma

Read More

The Future of Pharma Beyond Blockbusters

Article | March 4, 2020

We’ve all heard the saying “treat the patient, not the disease”, and this couldn’t be truer in today’s ever-changing pharmaceutical landscape. We are living in a time of revolution – advancements in genomics and technology are improving our ability to develop precise drugs and targeted therapies, rather than focusing on a one size fits all approach. Each individual’s genetic makeup is slightly different from everyone else’s,

Read More

Five Ways to Manage Your Trial Effectively in a Fast-Changing Global Environment

Article | March 4, 2020

Over the past half-century, clinical trials have grown increasingly complex. A flood of new data from novel sources combined with more elaborate study designs and tougher regulatory standards have lengthened timelines and hiked costs, contributing to a steady decline of efficiency. It all adds up: Nearly half of all drug launches underperform revenue expectations. And if that isn’t enough, the outbreak of COVID-19 worldwide is having an effect on how life sciences companies operate their businesses, including how clinical trials are conducted. Most clinical trial research organizations have tried to adapt by tweaking a platform here, adding a new app there, but this has only yielded patchwork systems of sites, spreadsheets and dashboards that further burden the process.

Read More

As Pandemic Continues, Rafael Pharmaceuticals Enrolls Patients in Phase III Pancreatic Cancer Trial

Article | March 4, 2020

That simple truth about the severity of the disease is one of the reasons that Rafael Pharmaceuticals is slowly continuing with a Phase III trial in metastatic pancreatic cancer during the COVID-19 pandemic. While many companies have paused enrollment in clinical trials during the outbreak, Cranbury, N.J,-based Rafael opted to continue to enroll patients in its Phase III AVENGER 500 study of its lead compound CPI-613 (devimistat) in combination with modified Folfirinox (mFFX) as first-line therapy for the disease. Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have. After discussing the matter of the trial with the company’s leadership team, Luther said they felt comfortable leaving the decision of whether or not the trial should continue to the conducting institute.

Read More

Spotlight

Nanomi

Over Nanomi: Nanomi ontwikkelt Nano en Microdeeltjes voor de farmaceutische industrie door middel van onze microfluidic Monosphere Technology. Wij zijn het “center of excellence for complex injectables” van Lupin ltd, een internationaal Indiaas farmaceutisch concern. Nanomi is een internationale, hightech omgeving met een leuke, informele werksfeer. Company Profile: Nanomi, based in Oldenzaal, is a drug delivery company developing pharmaceutical products based on nano- and microparticles. These particles are developed by using Nanomi’s microfluidic Monosphere Technology, enabling the manufacturing of very unique and uniform custom-made particles for a broad range of pharmaceutical products. In 2014 Nanomi was acquired by Lupin and became its center of excellence for complex injectables. Nanomi offers a highly innovative as well as dynamic environment and benefits from its parent company that was founded in 1968. Lupin is an innovation led transnational pharmaceutical company developing

Events